Lexeo Therapeutics, Inc. (LXEO) Dividend History

Company News

• Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

  Lexeo Therapeutics announces positive interim data for its gene therapy candidate LX2006 in treating Friedreich ataxia cardiomyopathy, with participants showing clinically significant improvements in cardiac biomarkers and increased frataxin expression. The company plans to initiate a registrational study by early 2026.

  GlobeNewswire Inc.
• 2 Stocks Riding the Biotech Surge With Major Catalysts Ahead

  The biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.

  Investing.com

  Featured Companies: TNXP
• Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

  Lexeo Therapeutics reported positive interim data from Phase 1/2 studies in Friedreich ataxia cardiomyopathy, showing LX2006 was well-tolerated and demonstrated evidence of sustained treatment effect. The company also initiated formal engagements with the FDA on surrogate endpoints for a registrational study and expects to provide an update by the end of 2024.

  GlobeNewswire Inc.
• Lexeo Therapeutics Announces Positive Interim Phase 1/2 - GlobeNewswire

  Lexeo Therapeutics announced positive interim data from its Phase 1/2 clinical trial of LX2006, a gene therapy candidate for the treatment of Friedreich ataxia cardiomyopathy. The data showed clinically meaningful improvements in cardiac biomarkers and increased frataxin protein expression in participants.

  GlobeNewswire Inc.
• What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock

  Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  Zacks Investment Research